Compugen Ltd. (CGEN) AI Stock Analysis

Compugen Ltd. is a clinical-stage company specializing in therapeutic discovery and development, conducting research and commercializing product candidates across Israel, the United States, and Europe. Focused on immuno-oncology, its pipeline features COM701, an anti-PVRIG antibody in Phase I trials for solid tumors; COM902, targeting TIGIT in Phase I trials for advanced malignancies; and Bapotulimab, targeting ILDR2 in Phase I studies. It also develops AZD2936, an anti-TIGIT/PD-1 bispecific antibody in Phase I/II trials for metastatic non-small cell lung cancer. Compugen collaborates with Bayer Pharma AG, Bristol-Myers Squibb, and Johns Hopkins School of Medicine.

Compugen achieved a 5-year revenue CAGR of 105.2% from FY2020 to FY2025. Annual revenue expanded from $6.0M in FY2021 to $33.5M in FY2023, declined 16.7% to $27.9M in FY2024, and rose 161.1% to $72.8M in FY2025. In FY2025, operating margin turned positive to 43.1%, resulting in net income of $35.3M and diluted EPS of $0.37, supported by gross margin of 87.3%. Over the trailing twelve months, revenue reached $74.0M with a profit margin of 47.6%. In the latest quarter ended June 30, 2026, quarterly revenue grew 107.0% year-over-year, while trailing twelve-month operating margin stood at -339.6%.

As of June 30, 2026, Compugen held $125.3M in cash and short-term investments against total debt of $3.0M, resulting in net cash of $122.3M. The company reported a current ratio of 5.72 and a debt-to-equity ratio of 0.03 alongside shareholders' equity of $88.7M. For FY2025, operating cash flow was $31.6M and free cash flow stood at $31.3M, following free cash flow of $49.5M in FY2024. Capital expenditures remained modest at $306,000 in FY2025, while the share count increased 10.9% over 5 years.

At $1.96 per share, Compugen trades at a trailing P/E of 5.2x and a forward P/E of 12.4x, both lower than the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value stands at $110.3M with an EV-to-revenue multiple of 1.5x and an EV-to-EBITDA of 3.6x, compared to the peer median EV-to-EBITDA of 12.0x. Over the past year, CGEN generated a return of 0.5%, lagging the S&P 500's 16.8% return. Over 5 years, the stock fell 69.2% while the S&P 500 gained 83.0%.

All 5 analysts covering Compugen rate the stock a Strong Buy, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $4.60, representing a 134.7% premium over the last close of $1.96. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $9.2M and an EPS of -$0.33. For the following fiscal year, 3 analysts project revenue will decrease 16.1% to $7.8M with an EPS of -$0.37. Compugen beat EPS estimates in 2 of the last 4 quarters, and the next earnings date is November 9, 2026.

This page is an AI-written research summary of Compugen Ltd. (CGEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CGEN income statement, CGEN balance sheet, CGEN key metrics, CGEN analyst forecast, CGEN chart. See the CGEN stock overview for the latest quote and news.